Table 2 Any treatment-related adverse event
From: Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
Grade 1–2 | Grade 3–4 | |
|---|---|---|
Symptom side effects | ||
Fatigue | 39(52%) | 0 |
Anorexia | 38(51%) | 0 |
Alopecia | 28(37%) | 0 |
Rash | 23(31%) | 0 |
Nausea | 22(29%) | 0 |
Vomiting | 19(25%) | 0 |
Diarrhoea | 15(20%) | 0 |
Arthralgia | 13(17%) | 0 |
Paraesthesia | 10(13%) | 0 |
Constipation | 6(8%) | 0 |
Pruritus | 5(7%) | 0 |
Abnormal lab examinations | ||
Anaemia | 51(68%) | 3(4%) |
Neutropenia | 43(57%) | 3(4%) |
hypothyroidism | 20(27%) | 0 |
Increased aminotransferases | 18(24%) | 2(3%) |
Thrombocytopenia | 16(21) | 0 |
hyponatremia | 10(13%) | 0 |
Increased creatinine | 9(12%) | 0 |
hyperuricemia | 6(8%) | 0 |
Hyperglycemia | 5(7%) | 0 |
Hypocalcemia | 3(4%) | 0 |